---
title: "Inferring tumor kinetics from single routine H&E biopsies to run virtual radiotherapy trials"
id: "medrxiv-9-effective-tumor-kinetics-inferred-from-single-routine-h-e-biopsies-enable"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-9-effective-tumor-kinetics-inferred-from-single-routine-h-e-biopsies-enable"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.10.26362768v1?rss=1"
published_at: "2026-09-12T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Inferring tumor kinetics from single routine H&E biopsies to run virtual radiotherapy trials
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-9-effective-tumor-kinetics-inferred-from-single-routine-h-e-biopsies-enable
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.10.26362768v1?rss=1)
- **Published At:** 2026-09-12T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Routine **H&E histopathology** captures spatial snapshots of tumor ecosystems but is often analyzed as texture without direct links to underlying tumor kinetics. The authors present a method to infer patient-specific mechanistic kinetics from a single routine H&E biopsy. - The approach fits cell-nucleus point patterns to an analytical two-point correlation function and power spectral density to recover per-patient parameters of a mechanistic **reaction-diffusion** model, specifically proliferation and diffusion rates. - The method was applied across eleven multicenter cohorts, producing derived metrics such as **dispersion length** and **front velocity** that define mechanistic phenotypes associated with progression-free and overall survival, adding prognostic information beyond routine covariates. - The paper illustrates counterfactual radiotherapy simulations in **glioblastoma**, using histology-calibrated growth kinetics to assign patients to hypofractionation for faster-growing tumors and dose-intensification for slower-growing tumors in an in silico trial. - In the virtual clinical trial, this histology-guided allocation improved restricted mean progression-free survival by 96.7 days compared with standard of care; the improvement was significant by permutation testing (p < 0.001) against random arm allocation. - The work enables a low-barrier translation from routine histopathology to mechanistically interpretable, forward simulations that can generate counterfactuals and inform personalized radiotherapy strategies. - Data used were secondary analyses of existing, de-identified datasets (including CPTAC cohorts via TCIA and UPenn-GBM) and institutional cohorts; no new human data were collected. The MD Anderson IRB approved the retrospective use with waivers where applicable (protocols listed in source). - The authors declared a patent application covering aspects of the described method and disclosed funders including MD Anderson, Austrian Academy of Sciences, NIH, NCI, and others.
## Clinical Analysis & Structured Key Points
Effective tumor kinetics inferred from single routine H&E biopsies enable counterfactual virtual radiotherapy trials | medRxiv Skip to main content Effective tumor kinetics inferred from single routine H&E biopsies enable counterfactual virtual radiotherapy trials View ORCID Profile Pirmin Schlicke , View ORCID Profile Caner Ercan , View ORCID Profile Sara Ranjbar , View ORCID Profile Ashlee N. Seldomridge , View ORCID Profile Sadhna Aggarwal , Adwait Mehta , View ORCID Profile Tania P. Sainz , View ORCID Profile Mohammad U. Zahid , Penny Fang , View ORCID Profile Veronika A. Hofmann , View ORCID Profile Stefano Pasetto , Tatiana Cisneros Napravnik , View ORCID Profile Nahum Puebla-Osorio , View ORCID Profile Christina Kuttler , Ann Klopp , View ORCID Profile Lauren Colbert , View ORCID Profile Ashley M. Holder , View ORCID Profile Roi Weiser , Steven H. Lin , View ORCID Profile Carlos A. Torres-Cabala , View ORCID Profile Francisco Vega , Yinyin Yuan , View ORCID Profile Heiko Enderling doi: https://doi.org/10.64898/2026.09.10.26362768 Pirmin Schlicke 1 University of Salzburg; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Pirmin Schlicke For correspondence: pirmin.schlicke{at}plus.ac.at Caner Ercan 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Caner Ercan Sara Ranjbar 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sara Ranjbar Ashlee N. Seldomridge 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ashlee N. Seldomridge Sadhna Aggarwal 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Sadhna Aggarwal Adwait Mehta 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tania P. Sainz 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Tania P. Sainz Mohammad U. Zahid 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Mohammad U. Zahid Penny Fang 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Veronika A. Hofmann 3 Technical University of Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Veronika A. Hofmann Stefano Pasetto 4 Arthrex Inc. Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Stefano Pasetto Tatiana Cisneros Napravnik 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nahum Puebla-Osorio 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Nahum Puebla-Osorio Christina Kuttler 3 Technical University of Munich; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Christina Kuttler Ann Klopp 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Lauren Colbert 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Lauren Colbert Ashley M. Holder 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ashley M. Holder Roi Weiser 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Roi Weiser Steven H. Lin 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Carlos A. Torres-Cabala 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Carlos A. Torres-Cabala Francisco Vega 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Francisco Vega Yinyin Yuan 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Heiko Enderling 2 The University of Texas MD Anderson Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Heiko Enderling Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Routine H&E-histopathology captures spatial snapshots of tumor ecosystems, yet computational pathology largely treats them as textures without explicit links to underlying kinetics. We show that patient-specific parameters of a mechanistic reaction-diffusion model can be inferred from a single biopsy. Cell-nucleus point patterns are fitted jointly to the analytical two-point correlation function and power spectral density, recovering patient-specific mechanistic proliferation and diffusion rates across eleven multicenter cohorts. Derived dispersion length and front velocity define mechanistic phenotypes stratifying progression-free and overall survival and adding information independent of routine covariates. We illustrate counterfactual radiotherapy simulations in glioblastoma and show that a virtual clinical trial deescalating histology-calibrated faster-growing tumors to hypofractionation while dose-intensifying slower-growing tumors adds 96.7 days of restricted mean progression-free in silico survival over standard of care (permutation p<0.001 against random allocation to the same arms). This provides a low-barrier transition from routine histopathology to mechanistically interpretable model-based forward simulations. Competing Interest Statement PS and HE declare that a patent application has been filed covering aspects of the method described in this publication. No other competing interests are declared. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center gave ethical approval for this work (IRB protocols 2023-0971, 2025-0243 and PA17-0191), including a waiver of informed consent for the retrospective use of these de-identified institutional datasets (melanoma, cervical cancer, esophageal cancer). All other cohorts analyzed in this study (CPTAC cohorts via TCIA, UPenn-GBM, and the ovarian cohort of Boehm et al.) are existing and publicly available datasets that were released under the approvals of the original studies and referenced in the manuscript. No new human data or samples were collected for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability This study is a secondary analysis of already existing, de-identified human data. The whole-slide images and the clinical records were collected, consented and released by the Clinical Proteomic Tumor Analysis Consortium and the associated repositories under their own approvals, and are publicly available as cited in the Data availability statement. No new human data were collected. Unless otherwise stated, the data sets analyzed in this study are published, referenced, and publicly available online through the referenced locations. Some data used in this publication were generated by the National Cancer Institute Clinical Proteomic Tumor Analysis Consortium (CPTAC). The CPTAC whole-slide imaging data analyzed in this study are publicly available through The Cancer Imaging Archive (TCIA): CCRCC (https://doi.org/10.7937/k9/tcia.2018.oblamn27), GBM (https://doi.org/10.7937/K9/TCIA.2018.3RJE41Q1), HNSCC (https://doi.org/10.7937/K9/TCIA.2018.UW45NH81), LSCC (https://doi.org/10.7937/K9/TCIA.2018.6EMUB5L2), LUAD (https://doi.org/10.7937/K9/TCIA.2018.PAT12TBS), and PDA (https://doi.org/10.7937/K9/TCIA.2018.SC20FO18). UPenn-GBM data are available through TCIA (https://doi.org/10.7937/TCIA.709X-DN49). Ovarian cancer data associated with Boehm et al. are available through the original publication. The de-identified institutional clinical data sets are available from the corresponding author Heiko Enderling and the respective data owners upon reasonable request with completion of data-sharing agreements, subject to institutional and regulatory policies. Funder Information Declared The University of Texas MD Anderson Cancer Center Austrian Academy of Sciences, https://ror.org/03anc3s24 Swiss National Science Foundation Jayne Koskinas Ted Giovanis Foundation for Health and Policy National Institutes of Health American College of Surgeons Department of Defense National Cancer Institute Leukemia & Lymphoma Society Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 12, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Effective tumor kinetics inferred from single routine H&E biopsies enable counterfactual virtual radiotherapy trials Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Effective tumor kinetics inferred from single routine H&E biopsies enable counterfactual virtual radiotherapy trials Pirmin Schlicke , Caner Ercan , Sara Ranjbar , Ashlee N. Seldomridge , Sadhna Aggarwal , Adwait Mehta , Tania P. Sainz , Mohammad U. Zahid , Penny Fang , Veronika A. Hofmann , Stefano Pasetto , Tatiana Cisneros Napravnik , Nahum Puebla-Osorio , Christina Kuttler , Ann Klopp , Lauren Colbert , Ashley M. Holder , Roi Weiser , Steven H. Lin , Carlos A. Torres-Cabala , Francisco Vega , Yinyin Yuan , Heiko Enderling medRxiv 2026.09.10.26362768; doi: https://doi.org/10.64898/2026.09.10.26362768 Share This Article: Copy Citation Tools Effective tumor kinetics inferred from single routine H&E biopsies enable counterfactual virtual radiotherapy trials Pirmin Schlicke , Caner Ercan , Sara Ranjbar , Ashlee N. Seldomridge , Sadhna Aggarwal , Adwait Mehta , Tania P. Sainz , Mohammad U. Zahid , Penny Fang , Veronika A. Hofmann , Stefano Pasetto , Tatiana Cisneros Napravnik , Nahum Puebla-Osorio , Christina Kuttler , Ann Klopp , Lauren Colbert , Ashley M. Holder , Roi Weiser , Steven H. Lin , Carlos A. Torres-Cabala , Francisco Vega , Yinyin Yuan , Heiko Enderling medRxiv 2026.09.10.26362768; doi: https://doi.org/10.64898/2026.09.10.26362768 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (899) Anesthesia (330) Cardiovascular Medicine (4804) Dentistry and Oral Medicine (478) Dermatology (414) Emergency Medicine (648) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1625) Epidemiology (15924) Forensic Medicine (32) Gastroenterology (1202) Genetic and Genomic Medicine (7037) Geriatric Medicine (732) Health Economics (1064) Health Informatics (5032) Health Policy (1432) Health Systems and Quality Improvement (1757) Hematology (584) HIV/AIDS (1343) Infectious Diseases (except HIV/AIDS) (16282) Intensive Care and Critical Care Medicine (1170) Medical Education (667) Medical Ethics (153) Nephrology (722) Neurology (7260) Nursing (366) Nutrition (1080) Obstetrics and Gynecology (1240) Occupational and Environmental Health (1004) Oncology (3600) Ophthalmology (1049) Orthopedics (397) Otolaryngology (451) Pain Medicine (470) Palliative Medicine (139) Pathology (706) Pediatrics (1795) Pharmacology and Therapeutics (737) Primary Care Research (765) Psychiatry and Clinical Psychology (5886) Public and Global Health (9742) Radiology and Imaging (2412) Rehabilitation Medicine and Physical Therapy (1448) Respiratory Medicine (1247) Rheumatology (640) Sexual and Reproductive Health (771) Sports Medicine (578) Surgery (775) Toxicology (107) Transplantation (304) Urology (290)
## Related Clinical Research

- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Arginine supplements and immune recognition: mouse study links arginine to improved cancer and vir](https://medichelpline.com/clinical-feed/medical-news-today-0-could-arginine-supplements-help-boost-immune-responses-to-cancer-viruses.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [PANoptosis in Diabetes and Complications: Mechanisms, Evidence Gaps, and Therapeutic Prospects](https://medichelpline.com/clinical-feed/frontiers-in-immunology-18-the-role-of-panoptosis-in-diabetes-and-its-complications-mechanisms-and.md)
- [Sellas Phase 3 REGAL trial for galinpepimut-S faces delays and likely negative outcome in AML](https://medichelpline.com/clinical-feed/stat-news-1-stat-a-sellas-immunotherapy-study-long-delayed-will-end-in-failure.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.